Carregant...
Adaptive randomized phase II design for biomarker threshold selection and independent evaluation
BACKGROUND: Frequently a biomarker capable of defining a patient population with enhanced response to an experimental agent is not fully validated with a known threshold at the start of a phase II trial. When such candidate predictive markers are evaluated and/or validated retrospectively, over-accr...
Guardat en:
| Publicat a: | Chin Clin Oncol |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2014
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4255950/ https://ncbi.nlm.nih.gov/pubmed/25485277 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2304-3865.2013.12.04 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|